Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024-2028

Description

Leveraging integrated and point-of-care diagnostics with multiomics represents the most promising growth opportunity to advance molecular diagnostics for neurodegenerative diseases

Neurodegenerative diseases (NDD) pose significant challenges to healthcare systems and affect millions of people worldwide, making early detection crucial. While the current diagnostic strategy is predominantly brain imaging techniques, it is not performed until symptoms are more pronounced. Subtle changes occurring in neural cells during early progression cannot be detected by the structural or functional changes associated with NDDs.

This study is a comprehensive analysis that explores technological advancements, industry dynamics, strategic insights, and growth opportunities in molecular diagnostics for NDDs. It captures the role of leading companies, growing start-ups, and smaller companies with innovative product portfolios and an industry presence, key drivers and restraints, and strategic partnerships. The study also delves into funding, grants, mergers and acquisitions (M&As), and commercialization efforts.

Overall, this study aims to provide insights into the evolving landscape of molecular diagnostics for NDDs and implications for healthcare innovation and patient care.

Key Questions the Study Answers:

1. What are the different molecular diagnostics for NDDs?

2. What are the main challenges and complexities in the widespread adoption of molecular diagnostics compared to imaging diagnostics?

3. What are the primary sources of biomarkers used in NDDs? Who are the key and emerging participants in terms of innovation and technology in this space?

4. How are omics technologies, smart PoC devices, and exosome-mediated diagnoses emerging as novel molecular diagnostics modalities for NDDs? How do they improve accuracy?

5. What are the strategic implications of the emerging collaborations and M&As between academia and industry participants?

6. How do patents contribute to advancements in diagnostics and therapeutics for NDDs?

7. What are the growth opportunities for molecular diagnostics for NDDs?

Product Code: DAED

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on Molecular Diagnostics for the Neurodegenerative Diseases Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Growth Opportunity Analysis

Dementia Disease Burden Forecast for 2050
Insights into NDD Research: Trends in Publications and Clinical Trials, 2019-2024
NDDs: Overview and Importance of Early Diagnosis
Segmentation
Challenges in Early NDD Diagnosis
Diagnostic Modalities in the NDD Landscape
Sources of NDD Molecular Biomarkers
Scope of Analysis
NDD Diagnosis: Biomarker Sources, Sample Extraction, and Analytes
Biomarker Sources: A Comparative Analysis
Integrated Landscape of NDD Biomarkers

Growth Generator

Growth Drivers
Growth Restraints

Technology Analysis: CSF Biomarkers

CSF-based Molecular Diagnostics to Detect NDDs
Key Companies Developing CSF-based Molecular Diagnostics for NDDs
Key Biomarkers for Neurodiagnostics: CSF-based Biomarkers, Global, 2024

Technology Analysis: Blood Biomarkers

Blood-based Biomarkers in NDD Diagnosis
Key Companies Developing Blood-based Molecular Diagnostics for NDDs
Emerging Companies Developing Blood-based Molecular Diagnostics for NDDs
Key Biomarkers for Neurodiagnostics: Blood-based Biomarkers, Global, 2024

Technology Analysis: Salivary Biomarkers

Salivary Biomarkers: An Accessible and Painless Diagnostic Approach for NDDs
Emerging Companies Developing Saliva-based Molecular Diagnostics for NDDs

Technology Analysis: Urinary Biomarkers

Urinary Biomarkers for Early Diagnosis of NDDs
Emerging Companies Developing Urine-based Molecular Diagnostics for NDDs

Technology Analysis: Ocular Biomarkers

Ocular Biomarkers: A New Frontier in NDD Diagnosis
Neurobiomarkers: Molecular Alterations in the Ocular Space
Emerging Companies Developing Ocular-based Molecular Diagnostics for NDDs

Technology Analysis: Skin-based Biomarkers

Skin-based Biomarkers for NDDs

Summary of Key Biomarkers for NDD Molecular Diagnostics

Key Insights: Biomarker Utilization by Industry Participants in the NDD Diagnostics Space
Molecular Biomarkers: From Bench to Clinic, Impact Analysis

Clinical Trial Analysis

Notable Clinical Trials in NDD Molecular Diagnostics
European Platform for Neurodegenerative Disorders (EPND): A Collaborative Approach to Data and Sample Sharing

Emerging Trends in NDD Molecular Diagnostics

Databases and Biobanks: Catalysts for Biomarker Discovery in NDD Diagnosis
Epigenetic Alterations as NDD Biomarkers
Big Data-powered Multiomics for NDD Diagnosis
Exosomes: A Potential Candidate for Early NDD Diagnosis
Portable Molecular Diagnostic Devices Enabling Smart Diagnostics for NDDs

Key Participants' Strategic Recommendations

Synaps Dx, US
AgenT Biotech, France
Urvogelbio, India
Resonant, US
Neurodex, US

Stakeholder Initiatives

Notable NDD Diagnostics Collaborations and Clinical Alliances
Recent NDD Diagnostics Mergers and Acquisitions
Global Companies in NDD Diagnostics: Insight into Regional Adoption

Funding Analysis

Snapshot of Public Funding for Molecular Diagnostics of NDDs in the US, 2019-2024
Special Focus on NIH Funding for Molecular Diagnostics of AD, 2019-2024
EU R&D Projects, 2019-2023
Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2021-2024
Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2020-2023

Patent Analysis

IP Trends in the Molecular Neurobiomarker Industry, 2019-2024
Patents by Key Participants in the NDD Diagnostics Space, 2019-2024
Analysis of IP Trends in the Molecular Neurobiomarker Industry, 2019-2024

Analyst Perspectives

Molecular Diagnostics in NDDs: Technology, Innovation, and Application Impact Analysis
Commercial Availability of Different Molecular Diagnostic Technologies in the NDD Landscape
Molecular Diagnosis of NDDs: A Technology Road Map

Growth Opportunities

Growth Opportunity 1: Smart Diagnostics at the Point of Care for NDD Detection and Management
Growth Opportunity 2: Integrated Diagnostics for Comprehensive NDD Assessment
Growth Opportunity 3: Exosomics and Metabolomics in the NDD Space

Appendix

Technology Readiness Levels (TRLs): Explanation

Next Steps

Benefits and Impacts of Growth Opportunities
Next Steps
Take the Next Step
Legal Disclaimer